Caredx reports first quarter 2023 results

Brisbane, calif.--(business wire)--caredx, inc. (nasdaq: cdna) – the transplant company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today reported financial results for the first quarter ended march 31, 2023. first quarter 2023 highlights delivered record number of patient test results for allomap® and allosure® of approximately 49,900 tests, growing year-over-year by 17%, an.
CDNA Ratings Summary
CDNA Quant Ranking